Lisa Harding, MD, urges psychiatrists to gather histories, deprescribe safely, and send focused sleep referrals now that orexin agonists have arrived for narcolepsy.
|Videos|August 17, 2022
Substance Use Disorder: A Brain Disease
Author(s)Brian Hurley, MD, MBA, DFASAM
Medication, counseling, and support—just as important in substance use disorder treatment as any other brain disease.
Advertisement
Brian Hurley, MD, MBA, DFASAM, gives a summary on his talk on medication treatment and psychotherapy for substance use disorders from the
Dr Hurley is the Medical Director of the Substance Abuse Prevention and Control at the Los Angeles County Department of Public Health.
Advertisement
Related to this article
Real-world data links once-monthly Uzedy to fewer ER visits, better adherence, and lower costs—plus fewer bipolar I relapses when switching from pills.
Nearly half of US adults who drink and use cannabis combine them at once; cannabis use disorder drives the trend, signaling urgent screening needs.
Experts highlight biomarker-driven schizophrenia care—computational subtypes, muscarinic drugs, sharper negative-symptom scoring, and KCC2 targets—reducing trial-and-error prescribing.
Panelists explain why precision tools lag in schizophrenia care and highlight simple biomarkers, faster deals, and clinician-industry collaboration.
FDA grants Breakthrough Device status to NET Recovery’s tACS wearable, aiming to curb cocaine and meth use and close a major treatment gap.
Advertisement
Advertisement
Trending on Psychiatric Times
1
FDA Grants Clearance to Motivista, the First Authorized Treatment for Negative Symptoms of Schizophrenia
2
Vortioxetine's Effect on Cognitive Function in Older Adults With Major Depressive Disorder
3
Interventional Options for TRD: ECT, TMS, and Esketamine
4
Muscarinic Treatment for Schizophrenia: A Presynaptic Answer to a Presynaptic Problem
5